Understanding how antibodies targeting beta-amyloid affect blood vessels in the brain
Official title: Adverse Cerebrovascular Responses to Antibodies Targeting Beta-Amyloid
Funded at University of California-Irvine · NIH-10855824 · Data updated 2026-11-12
This study is looking at how certain antibody treatments for Alzheimer's might affect the brain's blood vessels and could cause problems, especially as people age or have certain genes, so we can find safer options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $2,342,415 |
| NIH project number | 1RF1NS134046-01A1 |
| Project ID | NIH-10855824 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with Alzheimer's disease or those at risk, particularly those who may be considering antibody therapies.
✕Less likely to help
Patients who are not affected by Alzheimer's disease or do not have risk factors for cerebrovascular complications may not benefit from this research.
What this research studies
This research investigates the adverse effects of monoclonal antibodies that target beta-amyloid, a protein associated with Alzheimer's disease, on the blood-brain barrier and cerebrovascular health. By studying mouse models, the researchers aim to understand the mechanisms behind complications such as Amyloid Imaging Related Abnormalities (ARIA) that can occur during treatment. The study will explore how factors like age and specific genetic variations influence these adverse responses, providing insights into safer therapeutic strategies for patients. Patients may benefit from a better understanding of the risks associated with current antibody treatments.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for Alzheimer's disease by minimizing adverse cerebrovascular effects.
How similar studies have gone: Previous research has shown promising results in understanding the effects of anti-Aβ therapies, but this specific investigation into cerebrovascular responses is novel.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Cribbs, David Hastings — University of California-Irvine
- Study coordinator: Cribbs, David Hastings
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.